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Providing therapies tailored to each patient is the vision of precision medicine, enabled by the increasing ability to capture extensive data
about individual patients. In this position paper, we argue that the second enabling pillar towards this vision is the increasing power of
computers and algorithms to learn, reason, and build the ‘digital twin’ of a patient. Computational models are boosting the capacity to
draw diagnosis and prognosis, and future treatments will be tailored not only to current health status and data, but also to an accurate
projection of the pathways to restore health by model predictions. The early steps of the digital twin in the area of cardiovascular medi-
cine are reviewed in this article, together with a discussion of the challenges and opportunities ahead. We emphasize the synergies be-
tween mechanistic and statistical models in accelerating cardiovascular research and enabling the vision of precision medicine.
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Providing therapies that are tailored to each patient, and that maxi-
mize the efficacy and efficiency of our healthcare system, is the broad
goal of precision medicine. The main shift from current clinical prac-
tice is to take inter-individual variability into greater account.
This exciting vision has been championed by the -omics revolution,
i.e., the increasing ability to capture extensive data about the patho-
physiology of the patient.1,2 This -omics approach has already deliv-
ered great achievements, especially in the management of specific
cancer conditions.3 Nevertheless, the initial conception of precision
medicine has already been criticized for being too centred in genom-
ics and failing to address challenges of clinical management.4 The con-
cept is thus gradually widening, shifting from the original gene-centric
perspective to the wide spectrum of lifestyle, environment, and biol-
ogy data.5,6
In this context, we argue that the definition of optimal therapy
options requires a mechanistic understanding that links all levels from
genetic and molecular traces to the pathophysiology, lifestyle and en-
vironment of the patient, and back. Precision medicine requires, not
only better and more detailed data, but also the increasing ability of
computers to analyse, integrate, and exploit these data, and to con-
struct the ‘digital twin’ of a patient. In health care, the ‘digital twin’
denotes the vision of a comprehensive, virtual tool that integrates co-
herently and dynamically the clinical data acquired over time for an
individual using mechanistic and statistical models.7 This borrows but
expands the concept of ‘digital twin’ used in engineering industries,
where in silico representations of a physical system, such as an engine
or a wind farm, are used to optimize design or control processes,
with a real-time connection between the physical system and the
model.8
This position paper claims that precision cardiology will be deliv-
ered in a synergetic fashion that combines induction, by using statis-
tical models learnt from data, and deduction, through mechanistic
modelling and simulation integrating multiscale knowledge and data.9
These are the two pillars of the digital twin (Figure 1). We review the
state of the art of the interplay between such models that supports
this vision, considering that there are already excellent independent
review papers in the fields of statistical14–16 and mechanistic17,18
models for cardiovascular medicine.
Mechanistic models encapsulate our knowledge of physiology and
the fundamental laws of physics and chemistry. They provide a frame-
work to integrate and augment experimental and clinical data, ena-
bling the identification of mechanisms and/or the prediction of
outcomes, even under unseen scenarios without the need for
retraining.19 Examples of such mechanistic models are the bidomain
equations for cardiac electrophysiology20 or the Navier–Stokes
equations for coronary blood flow.21 In a complementary manner,
statistical models encapsulate the knowledge and relations induced
from the data. They allow the extraction and optimal combination of
individualized biomarkers with mathematical rules. Examples of stat-
istical models applied to computational cardiology are random for-
ests for assessment of heart failure severity22 or Gaussian processes
to capture heart rate variability.23
There are clinical needs that can be solved with a single modelling
approach. But both mechanistic and statistical models have
limitations that can be addressed by combining them. Mechanistic
models are constrained by their premises (assumptions and princi-
ples), while statistical models are constrained by the observations
available (the amount and diversity of data). A mechanistic model
may be a good choice when a good understanding of the system is
available. A statistical model, on the other hand, can serve to find pre-
dictive relations even when the underlying mechanisms are poorly
understood or are too complex to be modelled mechanistically. The
rest of the article describes the synergies between mechanistic and
statistic models (see Figure 2 for an overview), motivated by actual
clinical problems and needs, with specific representative components
of the digital twin. Supplementary material online reviews the model
synergies for exploiting and integrating clinical data.
Mechanistic and statistical model
synergy for improving clinical
decisions
Technical, ethical, and financial constraints limit the data acquisition
needed to assist clinical decision-making.14,15 Synergy between mech-
anistic and statistical models has shown value in aiding diagnosis,
treatment, and prognosis evaluation. A fully developed digital twin
will combine population and individual representations to optimally
inform clinical decisions (Figure 3).
Model synergy in aiding diagnosis
Models can pinpoint the most valuable piece of diagnostic data. An
example is the simulation study that revealed that fibrosis and other
pulmonary vein properties may better characterize susceptibility to
atrial fibrillation.24 Models can also reliably infer biomarkers that can-
not be directly measured or that require invasive procedures. For in-
stance, the combination of cardiovascular imaging and computational
fluid dynamics enables non-invasive characterizations of flow fields
and the calculation of diagnostic metrics in the domains of coronary
artery disease, aortic aneurysm, aortic dissection, valve prostheses,
and stent design.25–29
The key to guide diagnosis is the personalization of a mechanistic
model to the actual health status of the patient as captured in avail-
able clinical data. In this personalization process, statistical models en-
able robust and reproducible analysis of clinical data and infer missing
parameters. An example of this synergy is the assessment of left ven-
tricular myocardial stiffness and decaying diastolic active tension by
fitting mechanical models to pressure data and images during dia-
stole.30,31 Another example is the non-invasive computation of pres-
sure drops in flow obstructions,32,33 such as aortic stenosis or aortic
coarctation, which has been proven more accurate than methods
recommended in clinical guidelines.34 Models have also been used to
derive fractional flow reserve from computed tomography (CT) to
non-invasively identify ischaemia in patients with suspected coronary
artery disease, avoiding invasive catheterized procedures.29,35–37
Some diagnostic medical devices based on personalized mechanis-
tic models have already reached their industrial translation and clinic-
al adoption. HeartFlow FFRCT Analysis (HeartFlow, USA) and
CardioInsight (Medtronic, USA) use patient-specific mechanistic





































..models to non-invasively calculate clinically relevant diagnostic
indexes and have received clearance from the USA Food and Drug
Administration (FDA).38 HeartFlow predicts fractional flow reserve
by means of a personalized 3D model of blood flow in the coronary
arteries.36 In the CardioInsight mapping system, the electrical activity
on the heart surface is recovered from body surface potentials using
a personalized model of the patient’s heart and torso.39
Model synergy in guiding treatments
A digital twin may indicate whether a medical device or pharmaceut-
ical treatment is appropriate for a patient by simulating device re-
sponse or dosage effects before a specific therapy is selected.
The benefits of cardiac resynchronization therapy (CRT) have
been demonstrated in patients with prolonged QRS duration.
However, uncertainty remains in patients with more intermediate
electrocardiogram (ECG) criteria.40 To guide decision-making in this
‘grey zone’, approaches using mechanistic modelling have investigated
the role of different aetiologies of mechanical discoordination in CRT
response.10 For example, a novel radial strain-based metric was
defined based on simulations of the human heart and circulation to
differentiate patterns of mechanical discoordination, suggesting that
the response to CRT could be predicted from the presence of non-
electrical substrates.11 Statistical methods were used to verify
these findings in a clinical cohort, and the novel index remained useful
in predicting response in the clinical ‘grey zone’, creating the oppor-
tunity to improve patient selection in the group with intermediate
ECG.
Another example is the improvements in ablation guidance of
infarct-related ventricular tachycardia, where the accurate identifica-
tion of patient-specific optimal targets is provided before the clinical
procedure.41 Mechanistic models can propose novel electro-
anatomical mapping indices to locate critical sites of re-entry forma-
tion in scar-related arrhythmias, aid acquisition and quantitative inter-
pretation of electrophysiological data, and optimize future clinical
use.42
The industrial translation and clinical adoption of models for guid-
ing treatment are exemplified by the optimal planning of valve pros-
thesis with the HEARTguideTM platform (FEops nv, Belgium), or by
the platform to guide ventricular tachycardia ablations (inHeart,
France).
Figure 1 The two pillars of the digital twin, mechanistic and statistical models, illustrating its construction and four examples of use: a1,10 a2,11
b1,12 b2.13






































































Model synergy in evaluating prognosis
While statistical modelling allows for categorizing patients based on
the probability of various outcomes, mechanistic modelling provides
more insights to support or reject the categorization.
For example, model synergies represent an exciting approach to
interpret structure–function relationships and improve risk predic-
tion in inherited disease conditions, such as hypertrophic cardiomy-
opathy (HCM). Relationships among specific ECG changes, ventricle
morphologies, and sudden cardiac death have been inferred from
observations.43,44 However, the complex process of translating
underlying heterogeneous substrates in HCM to ECG findings is still
poorly understood, and there exists a ‘grey zone’ of clinical decision-
making in the low-risk patient subgroups, specifically when deciding
on restriction of involvement in professional sports.45 In this context,
by using methods of statistical inference and mathematical modelling
(see Figure 4), HCM patients were categorized into phenogroups
based on ECG biomarkers extracted from 24-h ECG recordings,48
and the aetiology of each ECG phenogroup linked with different
underlying substrates, suggesting ion-channel and conduction system
abnormalities.46,47 The results directly highlighted the potential of
personalized anti-arrhythmic approaches in the treatment of HCM
patients, and addressed the low-risk patients, showing that a normal
ECG might indeed be the discriminatory factor signalling minimal
ionic remodelling, fibrosis, disarray, and ischaemia in these ‘grey zone’
patients.
Models have also been used in the prediction of arrhythmic events
in post-myocardial infarction, outperforming existing clinical metrics
including ejection fraction.49 When the amount of data is not suffi-
cient to inform state-of-the-art machine learning methods, statistical
methods can still prove useful. An example is the use of principal
component analysis to account for right ventricular motion in pre-
dicting survival in pulmonary hypertension,50 or to identify signatures
of anatomical remodelling that predict a patient’s prognosis following
CRT implantation.51
While statistical models allow predictions, mechanistic models pro-
vide the underlying explanations. Understanding the actual meaning of
the selected features improves the plausibility of findings and increases
their credibility. For both approaches, quantifying uncertainty of pre-
diction can help identify cases that may require further review, while
building trust in cases where models are shown to be robust.52,53
Mechanistic and statistical model
synergy to accelerate evidence
generation
While digital twin technologies in cardiology show promising re-
search results, only a small number of models have reached clinic-
al translation. The difficulties encountered include the need to
increase validation, lack of clinical interpretability, and potentially
obscure model failures.54 Therefore, solid evidence for the gener-
alization of preliminary findings and efficient testing strategies are
needed. Even when these barriers are overcome, rigid assessment
of algorithmic performance and quality control from regulatory
bodies can slow down the adoption. In this context, model syn-
ergy can be used to accelerate the integration of novel technolo-
gies into clinical practice by increasing clinical interpretability,
validating generality of findings, and accelerating regulatory deci-
sion-making.
Model validation towards generality of
findings
The goal after validating an initial concept is to extend it to a more
general patient cohort, with less controlled characteristics. The prob-
lem of sampling bias, based on both intrinsic (physiological) and ex-
trinsic (environmental) demographic heterogeneity of the
population, becomes relevant when implementing solutions for
broader patient cohorts.55,56 Consequently, models (as clinical guide-
lines) may need recalibrations when used on populations from differ-
ent countries or ethnicities, or even from different centres in the
same country. In recent years, only 6% of artificial intelligence algo-
rithms had external evaluation performed (note this is beyond the
minimum requirement of using the learning, validation, and testing
partitions of the data), and none adopted the three design criteria of
a robust validation: diagnostic cohort design, the inclusion of multiple
institutions, and prospective data collection.57 The quality of datasets
also needs to be thoroughly validated to avoid possible biases before
the models developed from them can be integrated in clinical deci-
sion-making.58
To address this issue, an increasing number of institutions are cre-
ating initiatives for data-sharing platforms, aiming at reusing existing
Figure 2 Conceptual summary of the main benefits of digital twin technologies.
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Figure 3 Envisioned clinical workflow using the fully developed digital twin concept. Population data, collected from preceding patients and study
cohorts, are used to create and validate statistical and mechanistic models, as well as to create a population-based digital twin (green). Novel patient
data are analysed with the help of the existing models and integrated to form the patient’s digital twin (purple). The comparison and interaction be-
tween digital twins give valuable insight (phenotyping, risk assessment, prediction of disease development. . .) that is clinically interpreted and com-
bined with traditional data to aid in the process of clinical decision-making. The digital twin develops in line with the patient’s condition—adjusting
and improving in accordance with the follow-up data. Resulting outcomes are supplemented to shape population data and refine the follow-up data.
Figure 4 Synergy between mechanistic and statistical models in the definition of electrocardiogram (ECG) biomarkers for the management of
hypertrophic cardiomyopathy.47,48































































































datasets and verifying published research works.59 Governments,
regulatory agencies, and philanthropic funders are promoting the
open science culture, enforcing publishing patient-level data by means
of compliance to product launching, funding application, and journal
publishing.60
Another approach to improve the generality of data is the gener-
ation of synthetic cases of a representative wider population. The
core idea is to expand the average mechanistic model to obtain pop-
ulations of models, all of them parameterized within the range of
physiological variability obtained by experimental protocols.61,62
Such an approach, which allows investigating many more scenarios
than possible experimental acquisitions, is not only able to evaluate
the impact of physiological variability but to explain the mechanisms
underpinning inter-individual variability in therapy response (e.g. ad-
verse drug reactions), and to identify sub-populations at higher
risk.63,64 Statistical shape modelling techniques can represent inter-
patient anatomical variability for a cohort, and be used in combination
of mechanistic models for clinical decision support systems.65
As in traditional scientific research, mechanistic and statistical mod-
els are complementary tools to verify the findings derived from one
another. Finding a mechanistic explanation of an inductive inference
from statistical models increases its plausibility, such as the redistribu-
tion of work in the left bundle branch block to explain the remodel-
ling pattern that predicts response to CRT.51 Equivalently,
data computed from mechanistic models need to be scrutinized
quantitatively as it was done in the comparison of clinical and simula-
tion groups to validate a model for acute normovolaemic
haemodilution.66
An important final remark is that randomized control trials will al-
ways be needed to establish evidence that can never be obtained
from large observational databases.67
Models as critical tools for accelerating
regulatory decision-making
Clinical decisions are built on evidence from bench to bedside.
Regulatory decisions, on the contrary, are often based on heteroge-
neous, limited, or completely absent human data, as in the case of ap-
proval for first-in-human clinical trials. In this regard, the results of
computational models can now be accepted for some regulatory
submissions.68,69 Digital evidence obtained using computer simula-
tions can be used for safety of therapy prior to first-in-human use, or
under scenarios not ethically possible in human.38 Computational
models have an increasingly important role in the overall product life
cycle management, proving useful in the processes of design opti-
mization for development and testing, supplemental non-clinical test-
ing, and post-market design changes and failure assessment.27
The development process for medical devices involves manufac-
turing and testing samples under a wide range of scenarios, which is
often time-consuming and financially overwhelming. Moreover, pre-
clinical testing conditions are often very simplified with respect to the
actual patient environment. Statistical and mechanistic models syner-
gistically offer to streamline this process, where statistical models can
be used to collect a representative virtual patient cohort, and mech-
anistic models can then be used to simulate the device behaviour
under defined scenarios. In this way, new devices can be tested in a
representative virtual patient population, thereby decreasing the
risk before moving to an actual clinical trial. An example is
HEARTguideTM (FEops nv, Belgium), where device–patient interac-
tions after transcatheter aortic valve implantation can be predicted.25
The augmentation of clinical trial design with virtual patients is also
an evolving idea.70–72 This would overcome limitations of current
empirical trials, where patients burdened with comorbidities or com-
plex treatment regimens are often excluded from the trials, and
enrolled individuals are handled under reductionist approaches,
assuming they share a common phenotype. Such approaches often
fail to capture differences in response to treatment.70 Alternatively,
computational evidence can inform collection of novel evidence
from clinical trials,13,38 where models can improve patient selection
by derived biomarkers and predictions. This offers an opportunity to
answer questions traditionally restricted by financial or ethical con-
siderations, and to investigate therapy efficacy in more clinically rele-
vant cases. Computational modelling can also facilitate safe methods
to explore treatment effects in sub-populations clinically more com-
plex to address, such as patients with rare diseases or paediatric
cohorts, and therefore may allow for insights not possible in the cur-
rent clinical trial practice.
One of the first examples in which digital evidence (i.e. an in silico
trial) replaced any additional clinical evidence was in the approval of
the Advisa MRI SureScan pacemaker (Medtronic, Inc.).73 Another
powerful example is a computer simulator of type 1 diabetes melli-
tus,74 which was accepted by the FDA as a substitute to animal trials
for the pre-clinical testing of control strategies in artificial pancreas
studies. Later, an investigational device exemption (i.e. the approval
needed to initiate a clinical study), issued solely on the basis of model-
ling testing, was granted by the FDA for a closed-loop control clinical
trial of the safety and effectiveness of the proposed artificial pancreas
algorithm.
In the context of drug safety and efficacy assessment, an unmet
need is filling the gaps between animal translation or in vitro prepara-
tions and prediction of the human response. Mechanistic models may
assist in scaling observations into humans.75 This is, for example, the
goal of the CIPA initiative,69 sponsored by the FDA among others,
aiming at facilitating the adoption of a new paradigm for assessment
of potential risk of clinical Torsades de Pointes, where mechanistic
models of human electrophysiology will play a crucial role. This is
reinforced by a recent study in which human in silico trials outper-
formed animal models in predicting clinical pro-arrhythmic cardio-
toxicity, so they might be soon integrated into existing drug safety
assessment pipelines.63
Finally, after a product is launched, mechanistic models can be still
used for post-market re-evaluation and failure assessment in order to
identify any potential underlying problems. This creates a valuable op-
portunity for simulations to evaluate any design changes planned for
next-generation productions, ultimately closing the product life cycle
loop, and demonstrating the ubiquitous presence and utility of statis-
tical and mechanistic models in the future of medical product
regulation.
Discussion
The digital twin, i.e., the dynamic integration and augmentation of pa-
tient data using mechanistic and statistical models, is the actual



























































.pathway towards the vision of precision medicine. Simple and frag-
mented components of the digital twin are already used in clinical
practice: a decision tree in a clinical guideline encapsulates the best-
documented evidence that is based in statistical and mechanistic
insights. The digital twin will gradually include tailored computer-
enabled decision points, and create the transition from healthcare
systems founded on describing disease to healthcare systems focused
on predicting response, and thus shifting treatment selection from
being based on the state of the patient today to optimizing the state
of the patient tomorrow.
Envisioned impact and timeline
The digital twin provides a pathway to map current patient observa-
tions into a predictive framework, combining inductive and deductive
reasoning. Early components of the digital twin are already making a
clinical impact. In a generic clinical workflow divided in the stages of
data acquisition, diagnosis, and therapy planning, computational mod-
els can provide value in the three stages, see Figure 5. To improve
data acquisition techniques, there are already statistical models to
automate the image analysis tasks.16 To provide better diagnosis, a
virtual fractional flow reserve can replace an invasive catheter,29,37 or
the body surface recordings can be mapped to the surface of the
heart.39 With regards to therapy planning, a virtual deployment of
the valve replacement25,76 or a roadmap to guide ablation proce-
dures77,78 represents existing techniques (statistical and mechanistic)
that have been implemented into the clinical workflow. These solu-
tions have thus met regulatory approval, where they are referred to
as ‘software as a medical device’, and where guidelines from the
International Medical Device Regulators Forum are accepted by the
EU and the USA.
A digital twin will follow the life journey of each person and har-
ness both data collected by wearable sensors and lifestyle informa-
tion that patients may register, shifting the clinical approach towards
preventive healthcare. A notable challenge is the integration of these
data with healthcare organizations, where security and confidentiality
of the sensitive information remain paramount.
The currently still fragmented and incipient concept of the
digital twin will be gradually crystallized and adopted during
the next 5–10 years. The holistic integration of a Digital Twin is
the aspiration that will be reached through two complementary
and synergetic pathways: the first is the refinement of key deci-
sion points in the management of cardiac disease, driven by per-
sonalized mechanistic models that are informed by key pieces of
patient’s data; and the second is the disease-centred optimization
of the patient’s lifetime journey through the healthcare system,
driven by statistical models being informed by the electronic
health record of a large population.
On the actual implementation of the digital twin, we envision that
the evolution will be towards a gradually better inter-operability of
current health information systems, leading to a distributed location
of the information. Digital twin users will mainly be citizens and physi-
cians, with different interfaces that retrieve the relevant data and trig-
ger the analysis capabilities hosted in the local device or remote
cloud resources. The analysis may also require specialized skills that
may be delivered by industry, or even by computational cardiologists in-
side healthcare organizations.
Organizational and societal challenges
ahead
Access to data is the main challenge in both the development and the
clinical translation of the digital twin, caused by infrastructural, regula-
tory, and societal reasons. Information systems and electronic health
records are fragmented, highly heterogeneous and difficult to inter-
operate. Information is often contained in unstructured format, and
its extraction requires either manual work or further research efforts
of automation through natural language processing technologies.79
Simulations may also require specialized skills and supercomputers.
Figure 5 The vision of a personalized in silico cardiology, where the digital twin informs all the stages through the clinical workflow. Models are
used (i) to optimize data acquisition and the information extracted from it, (ii) to evaluate current health status and inform diagnosis and risk stratifica-
tion, and (iii) to optimize clinical devices and drug selection to deliver a personalized therapy.























































..In this context, provision of digital twin technologies may be enabled
by cloud infrastructures (e.g. HeartFlow FFRCT Analysis).
Consent and confidentiality are key ingredients to address the so-
cietal concerns when handling the personal data needed to develop
and validate digital twin technologies. The EU General Data
Protection Regulation (GDPR) has imposed new legal requirements,
such as the right to withdraw consent and the right to be forgotten,
causing controversy about the cost and feasibility of its enforce-
ment.80 Any digital twin solution that holds enough information to
identify a patient needs to carefully watch these requirements, that
also apply to retrospective data and safety backups.
Potential professional, cultural, and
ethical issues
As more clinical tasks are performed by models, the fear of replace-
ment of physicians by machines may arise. In some scenarios,
machines may match or even outperform physicians.81 In other scen-
arios, human experts, by not practising on the easy problems solved
by the machine, may lose the skills that may still be needed when
dealing with difficult cases.
The second professional barrier is the mistrust that originates
from a ‘black box’, where predictions derived by algorithms are not
matched with a plausible explanation. Generation of evidence is one
clear way to generate trust. Another solution is to use methods to il-
lustrate the logic inside the box, including clustering and association
techniques,82 which may help to identify the causes and mechanisms.
From the patient’s perspective, personalization creates the oppor-
tunity of more involvement in healthcare decisions. Patients will be
empowered to better manage their disease using the digital twin to
gain information about their current and predicted state, and poten-
tially to adopt optimized lifestyle suggestions. A well-informed patient
shall have more efficient discussions with physicians, and consent and
decide faster on diagnostic or treatment procedures.
Finally, on the ethical side, there is a risk of models to create or ex-
acerbate existing racial or societal biases in healthcare systems: if a
group is misrepresented in the data used to train models, that group
may receive a sub-optimal treatment.83
Recommendations
The pathway to accelerate the clinical impact with digital twin tech-
nologies is to generate trust among researchers, clinicians, and
society.
Research communities shall avoid inflating expectations.
Claims about generality and potential impact should be based on
rigorous methodology, with external cohorts to demonstrate
the validity of inferences, and with the quantification of the un-
certainty of predictions.84 Any model is a simplified representa-
tion of the reality, with a limited scope and dependence on
assumptions made. The opportunity is an adequate handling of
these limitations, with models able to identify data inconsisten-
cies, and with data used to constrain and verify the model
assumptions.85
As an emerging field, the digital twin needs guidelines, gold-stand-
ards, and benchmark tests.86,87 Scientific organizations and regulatory
bodies have released guidelines that can be used to establish the level
of rigour needed for computational modelling.27 Such guidelines and
standards are useful tools as they allow regulators to judge computa-
tional evidence and industry to understand regulatory requirements
for computational models, leveraging a substantial part of the risk and
uncertainty associated to the development of these new technolo-
gies. They can even increase and facilitate their translational impact,
as the quality and robustness of the models and their reporting will
Take home figure The cardiovascular digital twin that will deliver the vision of precision medicine by the synergetic combination of computer-
enhanced induction (using statistical models learnt from data) and deduction (mechanistic modelling and simulation integrating multi-scale
knowledge).






























































































increase by adhering to such guidance during model development.
Further effort is needed to widen the scope of these first
multi-stakeholder consensuses involving industry, academia, and reg-
ulators. Current initiatives that develop visions, technologies, or infra-
structure relevant to the ‘digital twin’ community are Elixir (https://
elixir-europe.org/), FAIRDOM (https://fair-dom.org/), and EOSC
(https://ec.europa.eu/research/openscience/index.cfm? pg=open-sci
ence-cloud).
The education of citizens, care providers, physicians, and research-
ers in the uses and possibilities of digital twin technologies is key for
its adoption and acceptance. University education systems should
also allow for the exchange of knowledge at the earliest stages of the
career: medical students should have some computational training,
just as engineers in biomedical industry should be trained in cardi-
ology during their studies.88 And postgraduate training programmes
should bridge remaining cultural and language gaps between disci-
plines, such as our Personalised In-silico Cardiology EU funded
Innovative Training Network (https://picnet.eu).
Conclusion
Precision cardiology will be delivered, not only by data, but also by
the inductive and deductive reasoning built in the digital twin of each
patient. Treatment and prevention of cardiovascular disease will be
based on accurate predictions of both the underlying causes of dis-
ease and the pathways to sustain or restore health. These predictions
will be provided and validated by the synergistic interplay between
mechanistic and statistical models. The early steps towards this vision
have been taken, and the next ones depend on the coordinated drive
from scientific, clinical, industrial, and regulatory stakeholders in
order to build the evidence and tackle the organizational and societal
challenges ahead.
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Singer T, Polonchuk L. Recent developments in using mechanistic cardiac model-
ling for drug safety evaluation. Drug Discov Today 2016;21:924–938.
20. Tung L. A bi-domain model for describing ischemic myocardial D-C potentials.
1978. https://dspace.mit.edu/handle/1721.1/16177 (29 February 2020).
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